Royalty Report: Drugs, Disease, Therapeutic – Collection: 29157

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 10

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 10

Primary Industries

  • Drugs
  • Disease
  • Therapeutic
  • Pharmaceuticals
  • Cancer
  • Biotechnology
  • Drug Discovery
  • Autoimmune
  • Kidneys

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 29157

License Grant
The Company announced that the Licensor decided not to exercise its option under the product development and commercialization Agreement between the Licensor and the Licensee to License XL784 for further development and commercialization. The Licensee announced in October 2007 that a phase 2 trial of XL784 did not meet its primary endpoint of reducing proteinuria compared with placebo in patients with proteinuria associated with diabetic nephropathy. As a result of the Licensor's decision, the Licensee has the right to develop and commercialize XL784 either independently or in collaboration with third parties, subject to royalty payments to on sales of any products incorporating the compound. The Company itself does not intend to invest further in the development of this drug, but will seek a partner with which to take the compound forward.
Field of Use
XL784 is a potent small molecule inhibitor of the ADAM-10 metalloprotease enzyme, which plays a role in blood vessel formation and cell proliferation that can cause renal fibrosis and impairment.  Diabetic nephropathy (nephropatia diabetica), also known as Kimmelstiel-Wilson syndrome and intercapillary glomerulonephritis, is a progressive kidney disease caused by angiopathy of capillaries in the kidney glomeruli. It is characterized by nephrotic syndrome and diffuse glomerulosclerosis. It is due to longstanding diabetes mellitus, and is a prime cause for dialysis in many Western countries.  Nephropathy means kidney disease or damage. Diabetic nephropathy is damage to your kidneys caused by diabetes. In severe cases it can lead to kidney failure.  The kidneys have many tiny blood vessels that filter waste from your blood. High blood sugar from diabetes can destroy these blood vessels. Over time, the kidney isn't able to do its job as well. Later it may stop working completely. This is called kidney failure.

IPSCIO Record ID: 3490

License Grant
The Sublicensor agreed to grant the Sublicensee a worldwide subLicense for the development, manufacture and commercialization of RE-021 (DARA).  

The Licensing Agreement also enables the Licensee to sell the Licensed technology as a research product or subLicense the technology to other third parties as potential sources of revenue.

License Property
RE-021, a small molecule intended to treat focal segmental glomerulosclerosis (FSGS), a disease that causes nephrotic syndrome and kidney failure.  RE-021 is a small molecule angiotensin receptor blocker (ARB) and selective endothelin receptor antagonist (ERA). RE-021 has already been demonstrated safe in human clinical studies. RE-021 could be useful as a treatment for other nephropathies and recalcitrant hypertension.
Field of Use
The Sublicensee intends to develop DARA for orphan indications of severe kidney diseases including Focal Segmental Glomerulosclerosis (FSGS) as well as conduct proof-of-concept studies in resistant hypertension and diabetic nephropathy. Certain patient groups with severely compromised renal function exhibit extreme proteinuria resulting in progression to dialysis and a high mortality rate. DARA, with its unique dual blockade of angiotensin and endothelin receptors, is expected to provide meaningful clinical benefits in mitigating proteinuria in indications where there are no approved therapies.

IPSCIO Record ID: 365047

License Grant
The parties partnered in a Study of Sparsentan where the Licensor is entitled to compensation upon NDA submission.
License Property
Sparsentan, an investigational product candidate for the treatment of IgA nephropathy (“IgAN”). The Protect Study met its pre-specified interim primary efficacy endpoint with statistical significance, demonstrating a greater than threefold reduction of proteinuria from baseline after 36 weeks of treatment,
Field of Use
Field of use is for the treatment of IgA nephropathy (“IgAN”).

IgA nephropathy, a rare, immune complex mediated chronic glomerular disease.

Glomerular diseases affect the filtering units of your kidney, the glomeruli. Symptoms include foamy urine, pink urine, high blood pressure and swelling in your face, hands, ankles or feet. Many diseases can cause glomerular disease. The leading cause is diabetic nephropathy.

IPSCIO Record ID: 7434

License Grant
The Licensee entered into a Sublicense Agreement pursuant to which the Licensor agreed to grant a worldwide License for the development, manufacture and commercialization of DARA, an ARB and ERA which the Licensee is initially using in connection with the treatment of focal segmental glomerulosclerosis (or FSGS), and which we refer to as RE-021.  DARA (PS433540) is an Angiotesin Receptor Blocker (ARB) and Endothelin Receptor Antagonist (ERA) .
License Property
RE-021 is a small molecule intended to treat focal segmental glomerulosclerosis (or FSGS), a disease that causes nephrotic syndrome and kidney failure.  RE-021 is a small molecule angiotensin receptor blocker (ARB) and selective endothelin receptor antagonist (ERA). RE-021 has already been demonstrated safe in human clinical studies. RE-021 could be useful as a treatment for other nephropathies and recalcitrant hypertension.

IPSCIO Record ID: 230671

License Grant
The Company entered into an agreement with Licensor that provides the Company with an option to license the Licensor patent rights and know-how to develop and commercialize compounds (CTP-499 and each metabolite thereof) and products, as defined in the agreement.

Upon exercise of the option, the Company will have an exclusive, royalty-bearing right and license, including a right to sublicense, under Licensor intellectual property and joint intellectual property, to develop, manufacture, use and commercialize, including filing for, obtaining and maintaining regulatory approval for, products in all medical fields on a global basis.

License Property
PCS-499 (previously known as CTP-499), is an oral tablet that is an analog of an active metabolite of an already approved drug. The advantage of PCS-499 is that it potentially may work in many conditions because it has multiple pharmacological targets that it affects that are important in the treatment of these conditions. The compound has previously been shown to be safe and tolerable with a trend toward efficacy in diabetic nephropathy. The Comapny has identified other unmet medical need conditions where the use of PCS-499 may result in clinical efficacy. These include Necrobiosis Lipoidica (NL) and Radiation-Induced Fibrosis (RIF) in head and neck cancer patients. NL is a chronic, disfiguring condition for which most patients do not have any treatment options. It develops more commonly in women than in men on the lower extremities, and ulceration can occur in approximately 30% of NL patients, which may lead to more severe complications, such as deep tissue infections and osteonecrosis that can threaten life of the limb.
Field of Use
The compound has already been shown to be safe with a trend toward efficacy in diabetic nephropathy (DN).  Diabetic nephropathy is damage to your kidneys caused by diabetes. In severe cases it can lead to kidney failure. But not everyone with diabetes has kidney damage.

The Company has met with the FDA on the first indication, Necrosis Lipoidica (NL), a chronic, disfiguring condition for which most patients do not have any treatment options.  Necrobiosis lipoidica is a necrotising skin condition that usually occurs in patients with diabetes mellitus but can also be associated with rheumatoid arthritis. In the former case it may be called necrobiosis lipoidica diabeticorum (NLD).

IPSCIO Record ID: 1009

License Grant
The Company and its wholly owned subsidiary entered into a Sublicense Agreement with Licensee for the full world-wide rights to its dual-acting receptor antagonist of angiotensin and endothelin receptors (DARA) to another pharma.
License Property
Licensor acquired the DARA (previous development name, PS433540) in its acquisition of another company in December 2008. The compound possesses two clinically-validated mechanisms of action that selectively block two potent vasoconstrictor and mitogenic agents, angiotensin-II and endothelin 1, at their respective receptors. In previously-completed Phase IIb studies for hypertension, the drug was found to be safe and well tolerated, and demonstrated statistically significantly greater reductions in blood pressure compared with either placebo or irbesartan.
Field of Use
Licensee intends to develop DARA for orphan indications of severe kidney diseases, including focal segmental glomerulosclerosis (FSGS), as well as conduct proof-of-concept studies in resistant hypertension and diabetic nephropathy. The DARA, with its unique dual blockade of angiotensin and endothelin receptors, is expected to provide meaningful clinical benefits in mitigating proteinuria in indications for which there are no approved therapies.

IPSCIO Record ID: 304790

License Grant
Licensee of Sweden was granted (i) an exclusive license to certain patents and joint intellectual property developed with Licensor and (ii) a non-exclusive license to certain of Licensor know-how as necessary or useful to develop and commercialize Nefecon or other product candidates.
License Property
Nefecon, is a proprietary, novel oral formulation of budesonide, an established, highly potent local immunosuppressant. Nefecon is currently the only pharmaceutical candidate in development for IgAN that is intended to be disease-modifying. Nefecon targets the ileum, the distal region of the small intestine, which is the presumed origin of IgAN due to the ileum being the location of the highest concentration of the Peyer’s patches, which are responsible for the production of secretory immunoglobulin A, or IgA, antibodies. Nefecon has been granted orphan drug designation for the treatment of IgAN in the United States and the European Union.
Field of Use
The filed of use is for the treatment of the autoimmune renal disease IgA nephropathy, or IgAN for which there is a high unmet medical need and there are no approved treatments. IgAN is a progressive, chronic disease that over time results in deterioration of kidney function in patients, many of whom end up at risk of developing end-stage renal disease, or ESRD, with the need for dialysis or kidney transplant.

IgA nephropathy (IgAN), also known as Berger's disease or synpharyngitic glomerulonephritis, is a disease of the kidney (or nephropathy) and the immune system; specifically it is a form of glomerulonephritis or an inflammation of the glomeruli of the kidney. Aggressive Berger's disease (a rarer form of the disease) can attack other major organs, such as the liver, skin and heart.

Licensee is a clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs.  Licensee expects that Nefecon will be the first treatment on the market indicated for IgAN, and, that Nefecon can successfully treat IgAN patients, their kidney function will be preserved.

IPSCIO Record ID: 234465

License Grant
The Licensor entered into an agreement for the sale of Voclosporin with a undisclosed Licensee.
License Property
Voclosporin is an investigational drug for the treatment of LN, FSGS, and DES.

Dry Eye Syndrome (DES)
Focal segmental glomerulosclerosis (FSGS)
Lupus nephritis (LN)

Dry eye syndrome is caused by a chronic lack of sufficient lubrication and moisture on the surface of the eye

Focal segmental glomerulosclerosis (FSGS) is a cause of nephrotic syndrome in children and adolescents, as well as a leading cause of kidney failure in adults.

Lupus nephritis is inflammation of the kidney that is caused by systemic lupus erythematous (SLE).

Field of Use
This agreement pertains to the drug industry.

IPSCIO Record ID: 26536

License Grant
The Licensee announced that the Licensor decided not to exercise its option under the product development and commercialization Agreement between the Licensee and the Licensor to License XL647 for further development and commercialization. The Licensee reported in May 2007 that it had notified the Licensor of it's determination that it had achieved proof-of-concept for XL647 based on data from a phase 2 clinical trial, thereby triggering a 90-day review period in which the Licensor could exercise its option. As a result of the decision by the Licensor not to exercise its option, the Licensee retains the right to develop and commercialize XL647 either independently or in collaboration with third parties.
Field of Use
The Licensee intends to move forward with the full development of XL647 in patients with non-small cell lung cancer and potentially other indications.  XL647 is a potent inhibitor of multiple RTKs implicated in driving tumor cell proliferation and tumor vascularization (blood vessel formation). XL647 inhibits the EGF, HER2, and VEGF RTKs, each of which is a target of currently approved cancer therapies. In addition, XL647 inhibits EphB4, an RTK that is highly expressed in many human tumors and plays a role in promoting angiogenesis. In a broad array of preclinical tumor models including breast, lung, colon and prostate cancer, XL647 demonstrated potent inhibition of tumor growth and causes tumor regression. In cell culture models, XL647 retains significant potency against mutant EGFRs that are resistant to current EGFR inhibitors.

IPSCIO Record ID: 256221

License Grant
Licensor grants the Licensee of Sweden
–   an exclusive, including with regard to Licensor and its Affiliates, right and license under the Licensed Technology and Licensors rights in the Joint Technology to Exploit the Licensed Compounds and Licensed Products solely for the purpose of Developing, Manufacturing and Commercializing Licensed Products in the Field and in the Territory.
–  an exclusive, including with regard to Licensor and its Affiliates, right and license under the Licensor Acquired Technology to Develop, Manufacture and Commercialize the Licensed Compounds and Licensed Products in the Field and in the Territory.
–  an exclusive, including with regard to Licensor and its Affiliates, right and license and right of reference in the Territory under Licensor s and its Affiliates rights, titles and interests in and to the Regulatory Approvals, to Develop, Manufacture and Commercialize the Licensed Compounds and Licensed Products in the Field and in the Territory.

This agreement contains a non-exclusive grant-back from Licensee to Licensor.

License Property
The Licensor has certain proprietary compounds known as NHE3 inhibitors for use in the treatment of human diseases and disorders, and has filed an Investigational New Drug application for one of such compounds, designated as RDX5791.

The Lead Licensed Compound means the NHE3 inhibitor designated as RDX5791, which is the subject of the IBS-C IND and the Cardio/Renal IND, and any metabolites, salts, esters, free acid forms, crystal forms, free base forms, pro-drug forms, racemates and all optically active forms thereof.

The patents include Patent Family I regarding Compounds and Methods for Inhibiting NHE-Mediated Antiport in the Treatment of Disorders Associated with Fluid Retention or Salt Overload and Gastrointestinal Tract Disorders;Patent Family II regarding Methods For Diverting Sodium From Systemic Circulation;  Patent Family Ill regarding Compounds and Methods for Inhibiting NHE-Mediated Antiport in the Treatment of Disorders Associated with Fluid Retention or Salt Overload and Gastrointestinal Tract Disorders (Indanes);  and, Patent Family IV regarding Compounds and Methods for Inhibiting NHE-Mediated Antiport in theTreatment of Disorders Associated with Fluid Retention or Salt Overload and Gastrointestinal Tract Disorders (Multimers).

NHE3 inhibitor programme includes the Phase 2-ready lead compound RDX5791, for the treatment of complications associated with end-stage renal disease (ESRD) and chronic kidney disease (CKD). NHE3 is the sodium–hydrogen antiporter 3, a protein essential in the absorption of sodium in the intestines.

Field of Use
On this basis, the Parties plan to develop RDX5791 for use in ESRD and CKD in addition to IBS-C, and intend to evaluate possible development in other diseases that are a consequence of sodium and fluid overload.

End-Stage Renal Disease (ESRD) is a medical condition in which a person's kidneys cease functioning on a permanent basis leading to the need for a regular course of long-term dialysis or a kidney transplant to maintain life.
Chronic kidney disease (CKD) means your kidneys are damaged and can't filter blood the way they should. The main risk factors for developing kidney disease are diabetes, high blood pressure, heart disease, and a family history of kidney failure.
IBS-C is a type of IBS in which the abdominal discomfort or bloating happens with constipation. Generally, constipation is when stools don't pass often enough (less than three times per week).

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.